solute carrier family 10 member 2Genealiases: ASBT · IBAT · ISBT · NTCP2 · PBAM · PBAM1
Q-omics provides the consensus-scored SLC10A2 profile across patient tissues and cancer cell-line models. SLC10A2 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC10A2 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, SLC10A2 RNA expression shows 6,914 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, COAD, and TGCT as cancer lineages where SLC10A2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC10A2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC10A2 survival associations across molecular data types. SLC10A2 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC10A2 RNA expression–survival associations across cancer types. High SLC10A2 expression shows unfavorable associations in OV, LUSC, PAAD and LGG, but favorable associations in KIRC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC10A2 RNA expression.
This table summarizes SLC10A2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC10A2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC10A2 shows lower tumor expression in COAD, KICH, KIRP, LUAD and LUSC and higher tumor expression in KIRC. The COAD box plot shows higher SLC10A2 RNA expression in normal versus tumor tissue (log2 FC = −0.452, t-test p < 0.001).
This table shows molecular features associated with SLC10A2 in patient tissues and cancer cell lines. In patient samples, SLC10A2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC10A2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BONE and BREAST.
